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Nanostructured lipid carriers (NLCs) have emerged as versatile carriers to improve oral 
bioavailability of poorly water-soluble drugs as well as to protect labile drugs from degradation 
and metabolism. Prepared by blending solid and liquid lipids, the choice of liquid lipid can 
have a great influence on their physicochemical characteristics and stability. The present work 
investigated the impact of six different liquid lipids with diverse chemical structures and 
hydrophilic and lipophilic balance (HLBs) on the critical quality attributes (CQAs) and storage 
stability of NLCs with trimyristin as solid lipid. Resveratrol (RES) was used as model drug as 
its low water solubility, poor bioavailability, rapid metabolism and clearance from systemic 
circulation restricts its clinical use despite its wide spectrum of biological activities.  Liquid 
lipids investigated included, two triglycerides, one medium chain (C8) glycerol tricaprylate 
(GTC) and second, long chain (C18) glyceryl trioleate (GTO); two propylene glycol fatty acid 
esters, propylene glycol monocaprylate (PGMC) and propylene glycol monolaurate (PGML); 
fatty acid ester decyl oleate (DO) and a PEGylated lipid polyethylene glycol-8 caprylic/capric 
glycerides (PCG). Box–Behnken experimental design was employed to ascertain the effect of 
four independent factors viz. type of liquid lipid, amount of liquid lipid, amount of drug and 
surfactant concentration and interactions between these factors on the CQAs of NLCs as 
response variables viz. particle size (PS), polydispersity index, (PDI) zeta potential (ZP), drug 
encapsulation efficiency (EE), and drug loading (DL). The relationship between various factors 
and responses was established by response surface methodology (RSM). The oils with higher 
lipophilicity C18 triglycerides (GTO) and C18 fatty acid ester DO yielded NLCs with lower 
PS as compared to the oils with lower lipophilicity (PGC, PGMC and PGML). Although 
increasing the concentration of liquid lipids had an upward trend on the PS of NLCs, its PDI 
was more predominantly influenced by the nature of liquid lipid. The characteristic of the liquid 
lipid influenced the DL remarkably which varied from 2.94 to 7.56%. The ZP of nanoparticles 
varied from -21.3 to -39.9 mV with liquid lipids with free hydroxyl groups and higher HLB 
playing a more prominent role contributing to the increase in the negative surface charge. The 
characteristics of liquid lipid influenced the depression of melting point of RES with maximum 
distortion of the crystal lattice was caused by PGMC and least by GTO. The two, long chain 
oleates, DO and GTO exhibited a shift of lipid peak in NLCs to higher melting points (116 and 
111⁰C) than the less lipophilic liquid lipids (103-104⁰C). The attributes of liquid lipid also 
discriminate whether the particle growth during storage followed Oswald’s ripening or 
coalescence. NLC containing GTO exhibited the highest stability in terms of maintenance of 




liquid lipids and future strategy for rational design of stable NLC systems for delivery of 
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There has been tremendous increase in studies involving nanostructured lipid carriers (NLCs) 
in the last decade. NLCs  have emerged as effective and prominent alternative nanocarrier to 
emulsions, liposomes, solid lipid nanoparticles (SLNs) and their polymeric counterparts due to 
their numerous distinct advantages [1-3]. NLCs are promising delivery systems for carrying 
drugs to their site of action while protecting them from the degradation in the external 
environment [4, 5]. Their amicable physicochemical and biopharmaceutical properties have 
been widely studied for oral delivery of small and large molecules alike [6]. 
 
NLCs were typically developed in order to overcome the potential problems associated with 
solid lipid nanoparticles (SLN); which are limited in their drug loading capacity and potential 
drug expulsion during storage. Prepared from blend of solid and liquid lipids, NLCs have 
imperfect crystal structure owing to the presence of liquid lipid which allow more drug 
incorporation in their lipid matrix [7]. The diversity in chemistry and structural richness of 
lipids offer a wide spectrum to fabricate the NLCs with different characteristics and containing 
diverse active molecules. However, stability of NLCs is strongly affected by the type and the 
amount of liquid oil in the lipid matrix. Dispersion stability is enhanced when the oil 
concentration is increased, which leads to the decrease in the crystallization and melting point 
of the lipid matrix, polymorphic transformation rate is also increased that ends up with particles 
having more spherical shape, thus, particles retain their sphericity over longer period of time, 
accordingly, enhancing their suspension stability [8].  Thus, selection of liquid lipid is critical 
to the performance and stability of NLCs. Understanding the chemistry and physicochemical 
properties of the lipids is a prerequisite for successful formulation of stable NLCs with 
predictable biopharmaceutical properties. Though, researchers have employed myriad of liquid 
lipids [9] to prepare NLCs but there are a few reports of a direct comparison of the effect of 
liquid lipids on the quality parameters and stability of NLCs. Also little is known on the effect 
of type of liquid oil on the polymorphic transformations and lipid modification or interactions 
within NLCs [10].  
 
Resveratrol (RES) (3,4′,5-trans-trihydroxystilbene) is a naturally occurring phytoalexin which 
shows a wide spectrum of biological activity, including anti-tumour, anti-inflammatory, cardio 
and neuroprotective with anti-oxidative effects. RES is found to occur in red grapes, peanut 




recommended as a nutraceutical for its various beneficial actions [11]. Although range of 
promising biological effects of RES have been demonstrated, its clinical application is limited 
because of its low systemic availability and rapid clearance from the circulation [12]. 
Moreover, its low water solubility reduces the dissolution-rate limited cell absorption which 
further coupled with rapid degradation in gastro-intestinal tract leads to reduced oral 
bioavailability [13]. The therapeutic potential of RES can be realized in vivo for any clinical 
effect, only if the limitations bound to its bioavailability are overcome. NLCs present as 
promising drug delivery system, which could overcome bioavailability problems of RES with 
improved absorption and protection against rapid metabolism. 
 
 The aim of the present study is to investigate the effect of six different liquid lipids with 
varying chemical compositions, molecular structures and hydrophilic lipophilic balance (HLB) 
on the critical quality attributes (CQAs) and stability of NLCs with RES as a model drug 
(Table1). Two triglycerides, one medium chain, glycerol tricaprylate (GTC) and second long 
chain, glyceryl trioleate (GTO), two propylene glycol fatty acid esters, propylene glycol 
monocaprylate (PGMC) and  propylene glycol monolaurate (PGML), one fatty acid ester, decyl 
oleate (DO) and one PEGylated lipid polyethylene glycol-8 caprylic/capric glycerides (PCG) 
were employed along with trimyristin as solid lipid for preparation of NLCs using hot melt 
high pressure homogenization technique.   Box–Behnken experimental design was employed 
to examine the effect of four independent factors viz. type of liquid lipid, amount of liquid 
lipid, amount of drug and surfactant concentration and interactions between these factors on 
the CQAs of NLCs as response variables viz. particle size (PS), polydispersity index (PDI), 
zeta potential (ZP), drug encapsulation efficiency (EE), and drug loading (DL). The 
relationship between various factors and responses was established by response surface 
methodology (RSM) [14, 15]. Detailed thermal analysis was carried out using differential 
scanning calorimetry (DSC) to determine the effect of liquid lipids on the solid lipid as physical 
mixture and within the NLC formulation as well as on drug solubilisation. The effect of the 
liquid lipids was also evaluated on the storage stability of the NLCs over the period of six 
months by observing the changes in the PS, PDI, ZP, EE and DL and its ramification on 







2. Materials and methods  
2.1. Materials 
The following materials were used from the determined sources without further purification. 
Trimyristin (Dynasan 114) was kindly donated as a gift sample from Cremer oleo division, 
PEG-8 caprylic/capric Glyceride (Labrasol), propylene glycol monolaurate (Lauroglycol 90), 
propylene glycol monocaprylate (type II) NF (Capryol 90) were kindly supplied by Gattefosse. 
Glyceryl trioleate was purchased from Sigma-Aldrich, glycerol tricaprylate (Miglyol 808) was 
was generously supplied by Cremer and decyl oleate were kindly gifted by BSAF. Sodium 
cholate, Tween 80 and Span 80 were purchased from Sigma-Aldrich, UK. Lipoid S75, E80 and 
Phospholipon 90H was kind gift from Lipoid oleo division, Germany. Amicon 0.5 mL 
centrifugal tubes (3K Da molecular weight cut-off) was purchased from Spectrum Labs, USA. 
Resveratrol was purchased from Manchester Organics, UK. High performance liquid 
chromatography (HPLC) solvents and water were purchased from Fisher Scientific, UK.  All 
other chemicals were of analytical grade. Purified water was used throughout the study. 
 
2.2. Measurement solubility of resveratrol in liquid lipids 
RES solubility in each of the six liquid lipids was determined by adding an excess amount of 
drug (approximately 200 mg) to each of the individual liquid lipid (5 mL) in screw-capped 
bottle  [16]. After 24h of stirring, the sample was centrifuged at 13,000 rpm for 5 minutes and 
the clear supernatant layer was diluted with the mobile phase (acetonitrile: water) and analysed 
by a validated reverse phase HPLC method using C18 Luna column and detected at 306 nm 
[17].  
 
2.3. Preparation of resveratrol loaded NLCs (RES-NLCs)  
NLCs were prepared by hot melt homogenisation process. Briefly, a hot aqueous phase 
containing Tween 80 and sodium cholate (0.25%) was preheated to 70⁰C. Trimyristin was 
melted and either of the six liquid lipids PCG, PGMC, PGML, GTO, DO or GTC were 
subsequently added to it. RES was solubilized in mixture of soy phospholipid (S75), egg 
phospholipid (E80) both at a concentration of 0.1%w/w and Phospholipon 90H (0.3%w/w). 
This drug phospholipid mixture was added to the molten lipid phase. The resultant mix was 
left for continued mixing to get a uniform dispersion of lipid phase. The lipid phase was added 
to the preheated aqueous phase in a drop wise manner and homogenized for 10 minutes on a 




homogenized using high pressure homogenizer Nano DEE BEE (BEE International. USA) at 
10,000, 20,000 and 30,000 bar for 3, 3 and 5 cycles, respectively. The nanodispersion was left 
to cool at room temperature (20°C) for the re-crystallization of the lipid to yield six types of 
NLCs viz. RES-NLC-GTO, RES-NLC-GTC, RES-NLC-PCG, RES-NLC-PGMC, RES-NLC-
PGML and RES-NLC-DO. Blank NLCs (B-NLCs) without the drug were prepared using the 
exact procedure mentioned above but without incorporation of RES for each of the liquid lipids. 
 
2.4. Optimization by Box and Behnken design 
To investigate the effect of six different liquid lipids on the formulation of NLCs, 4-factor, 3-
level Box-Behnken design was employed to evaluate the main, interaction and quadratic effects 
of four independent variables at three levels on the five identified CQAs as dependent variables. 
Four critical independent variables were investigated namely; type of liquid lipid (D), 
concentration of liquid lipid (X1), Tween 80 concentration (X2), and amount of drug (X3). CQA 
is a physical, chemical, biological, or microbiological property or characteristic that should be 
within an appropriate limit, range, or distribution to ensure the desired product quality [18]. 
PS, PDI, ZP, EE and DL being the most influential parameters, which characterize the 
nanostructured drug delivery system were determined as CQAs and taken as response variables 
[19]. Table 2 shows the experimental design points with variables coded values (low, medium, 
and high) used in matrix of experiments with thirteen runs executed for each of the six liquid 
lipids totalling to 78 runs. Two-dimensional contour plots composed of the relation between 
two factors while the third factor being kept constant were generated by the Design Expert® 
software (Stat-Ease Design-Expert trial Version 9.0.4.1). The linear correlation plots of the 
actual experimental values were compared to the corresponding predicted values for each 
response for optimum model validation. The regression equation describing the effects of the 
variables on the responses in terms of linear, interactive and quadratic models was generated 
as given below: 
Y = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3+ b23X2X3+ b11X12 + b22X22 + b33X32      
Equation 1 
Where Y is the measured response associated with each factor level combination; b0 is an 
intercept; b11–b33 are regression coefficients computed from the observed experimental Y 
values; and X1, X2, and X3 are the coded levels of independent variables. The terms X1X2 and 
Xi2 (i = 1, 2, or 3) represent the interaction and quadratic terms, respectively [20]. The six 




of desirability functions and subjected to detailed physicochemical characterization and 
stability studies. 
2.5. Physicochemical characterization of RES-NLCs 
2.5.1. Particle size and polydispersity index  
The PS and PDI were measured using dynamic light scattering technique on a Malvern 
Zetasizer (Nano ZS, Malvern Ltd., Worcestershire, UK). Disposable polystyrene cells having 
10 mm diameter were employed to measure hydrodynamic diameter (ɀ-average) and PDI. All 
measurements were repeated three times for all the values at an angle of 173° at 25°C. 
 
2.5.2. Zeta potential measurements 
ZP reflects the electric charges on the particle surface. It is considered as a valuable parameter 
to predict the physical stability of colloidal system. ZP was determined by the measurement of 
the electrophoretic mobility using Malvern Zetasizer Nano ZS (Malvern Instruments, UK).  
 
2.5. 3.  Entrapment efficiency and drug loading  
The amount of free drug was determined by ultrafiltration method with 3 KDa molecular 
weight cut-off. Briefly, RES-NLC dispersion was placed into centrifugal filter tube and 
centrifuged at 13000 rpm for 60 min. After centrifugation, the amount of soluble free drug in 
the aqueous phase was detected by HPLC method at 306 nm. The total drug in NLCs was 
determined by adding 4 mL of tetrahydrofuran to 1 mL of nanoparticle dispersion to ensure 
that the lipid and the drug were completely dissolved. The solution was filtered through 
0.22 µm filter diluted with the mobile phase and analyzed by HPLC. The amount of drug 
encapsulated in NLCs was determined by the indirect method as the difference between total 
drug in the NLCs and free drug. This method is simple and widely used for determining the EE 
[14]. EE (%) and DL (%) were calculated as follow: 
 
EE (%) = Wtotal - Wfree ×100%                            Equation 2 
                          Wtotal 
DL (%) = Wtotal - Wfree ×100%                            Equation 3  
                        WLipids 
where Wfree is the amount of free drug in the supernatant; W total amount of RES added; Wlipids 





2.6. Differential scanning calorimetry (DSC)  
To discern the interaction between different liquid lipids and solid lipid; and liquid lipids and 
RES, DSC was performed on differential scanning calorimeter (MetllerToledo 823e 
instruments, Switzerland) measuring the melting enthalpy of bulk RES, trimyristin, physical 
mixture of trimyristin with different liquid lipids at three concentrations, physical mixture of 
RES with different liquid lipids also at the three concentrations. Samples were placed in a flat 
bottom 40µL aluminum pan and covered and sealed with pin-holed aluminum lid (Mettler 
Toledo, UK).   An empty aluminum pan was employed as the reference and each thermograph 
was baseline corrected. In order to study the effect of liquid lipid addition on the thermal 
behavior of the solid lipid, the heating runs were performed on physical mixtures from 25° to 
70°C, the heating rate was 10°C /min, with a nitrogen purge of 0.2 mL/min., then kept 
isothermal at 70°C for 60 min followed by cooling down to 0° C at a rate of 10 °C/ min, kept 
isothermal at 0°C for 2 min then heated again up to 300°C (10°C/min). 
 
For DSC studies on NLC formulations, the sample was accurately weighed and the heating 
runs were started from 25° to 300°C at scan rate of 10°C/min with a nitrogen purge of 
0.2 mL/min, then cooled down to 0°C, kept isothermal at 0°C for 2 min then heated to 300°C 
with heating rate of 10°C /min. The resulting thermograms were analyzed using Mettler StarE 
DB V9.10 software and comparison of melting enthalpy/g of the individual materials with the 
melting enthalpy/g of the NLC dispersion was made to estimate the rate of crystallinity of the 
sample. 
 
2.7. Storage stability  
Stability of the six optimized NLC formulations was evaluated for a period of six months. 
Briefly, RES-NLC-GTO, RES-NLC-GTC, RES-NLC-PCG, RES-NLC-PGMC, RES-NLC-
PGML and RES-NLC-DO were prepared and stored in sealed amber colour glass bottles at 
both 4⁰C and 20⁰C. Samples were withdrawn at one, three and six month intervals and 
characterized for PS, PDI , ZP %EE and %DL [21].  
 
2.8. Statistical analysis 
For the Box and Benkhen design, Analysis of Variance (ANOVA) provision available in the 
software (Stat-Ease Design-Expert trial Version 9.0.4.1) was used to establish the statistical 
validation of the polynomial equations generated by Design expert® between the dependent 




results were expressed as a mean ± SD. Two-way ANOVA followed by Bonferroni post-test 
was carried out to compare replicates (n=3) using the GraphPad Prism 5 software. Difference 
at p < 0.05 was considered statistically significant. 
3. Results and discussion  
3.1. Solubility of resveratrol in different liquid oils 
The drug carrying capacity of NLCs is directly dependent on the solubility of the respective 
drug in the lipid matrix and is one the of important determinant for the development of an NLC 
formulation. The drug should have high solubility in the lipids in order to achieve maximum 
entrapment  in the NLC matrix and also prevent any crystallisation of drug during storage [22]. 
RES exhibited highest solubility (112.28±6.81 mg/mL) in PCG (Labrasol) (Figure 1) which 
consists of 30% mono-,di- and triglycerides of C8 and C10 fatty acids, 50% of mono- and di-
esters of polyethylene glycol, 20% of free PEG 400  with high HLB of 14 [23].  Due to the 
ability of the long PEG chains to uphold more drug and high HLB value of Labrasol lead to its 
higher solubilizing capacity for RES. Labrasol as an excipient is known to increase the 
solubility and bioavailability of hydrophilic and hydrophobic drugs [24]. Hydrophobic liquid 
oils, GTO and DO, both esters of long chain fatty acid oleic acid with low HLB values showed 
least solubility for RES. The solubility in different carriers followed the pattern from order of 
high to low solubility of RES in various liquid lipid PGC ˃PGML˃PGMC˃GTC ˃ GTO˃ DO 
(Figure 1).  
 
3.2. Response surface methodology and optimization by Box and Behnken design  
3.2.1. Response surface analysis and fitness to the model 
 The influence of type of liquid lipid employed in each formulation, liquid lipid concentration, 
surfactant concentration and the amount of drug on CQAs taken as dependent variables viz. 
PS, PDI, ZP, %EE and %DL are graphically represented as contour plots (Figure 2. A & B). 
The contour plots demonstrate the effect of the interaction between the liquid lipid 
concentration with different amounts of drug at medium level of Tween 80 (Figure 2.A) and 
interaction between the liquid lipid concentration and the Tween 80 concentration at a low level 
of drug for each type of liquid lipid on the selected CQAs (Figure 2.B).  
The ANOVA of the regression model demonstrates that the model is highly significant as 
evident from the high F values (F model for PS =4.91, PDI=2.58, ZP= 2.59, EE=4.79 and 
DL=21.80). Values of "Prob > F" less than 0.05 for all responses indicate model terms are 




fitting the data and predicting the response. It can be seen from predicted versus actual plots 
(Figure S1 and S2) that the experimentally measured values are well in line with the predicted 
values. Furthermore, adequate precision measures the signal to noise ratio. A ratio greater than 
4 is desirable. The ratio of 8.98 (PS), 8.25 (PDI), 7.28 (ZP) 9.58 (EE) and 15.78 (DL) indicates 
an adequate signal and model can be used to navigate the design space. A quadratic model was 
implemented for all responses and polynomial equations were generated which explain the 
individual and interaction effects of independent factors on the dependent variables [25]. 
 
3.2.2. Influence of investigated parameters on PS 
The PS was clearly affected by the attributes of liquid lipid incorporated in the NLCs. The more 
lipophilic oils, the two triglycerides GTO, GTC and the long chain fatty acid ester DO that 
were more miscible with the solid lipid resulted in lower PS as compared to the hydrophilic 
oils (PGC, PGMC and PGML). We hypothesize that lipophilic oils produced more stable NLCs 
with lower PS because the miscible oils likely promote a more mobile interface resulting in 
increased mobility of surfactant at the particle surface which allowed the surfactant molecules 
to move around the interface during the polymorphic transformation to stabilize 
uncovered hydrophobic surfaces. Higher PS upon the inclusion of Labrasol has been 
previously reported [26]. Further for each of the six RES-NLCs, the quadratic equations 




E-003×X32                                                                                                                Equation 4     
For DO  
PS=+122.61144+28.18333×X1-82.71333×X2-0.48106×X3-
88.83333×X1×X2+0.12487×X1×X30.083767×X2×X3+23.18667×X12+52.46000×X22+2.32167
E-003×X32                                                                                                                 Equation 5         
For PCG 
PS= +119.05913+32.47333× X1-79.84333×X2-0.51231×X3-88.83333× X1×X2+0.12487× X1× 







PS= +108.17029+82.83333× X1-50.11333× X2-0.63466× X3-88.83333× X1×X2+0.12487× X1 
× X3-0.083767×X2×X3+23.18667×X12+52.46000×X22+2.32167E-003×X32                    
Equation 7                                                    
For GTO     
PS=+121.03423+39.50833× X1-72.21333×X2-0.57738× X3-88.83333× X1×X2+0.12487× X1 
× X3-0.083767×X2×X3+23.18667×X12+52.46000×X22+2.32167E-003×X32                     
Equation 8                                                      
For PGML 
PS=+103.85404+71.22833× X1-70.10833× X2-0.52336× X3-88.83333× X1×X2+0.12487× X1× 
X3-0.083767×X2×X3+23.18667×X12+52.46000×X22+2.32167E-003×X32              Equation 9                                                       
Positive sign before a factor in polynomial equations suggest a synergistic effect and signifies 
that the response increases with the factor, whereas a negative sign means the response and 
factors have reciprocal relation. The magnitudes of the coefficients indicate the degree of 
contribution of the factor to the response, the influence of six liquid lipids on PS was in the 
following order PGMC>PGML>GTC>GTO>PCG>DO (equations 4-9).This is further vivid in 
perturbation plots (Figure 3.a) where steeper curvature for PGMC and PGML entail that these 
two liquid lipids had a higher impact on PS than other liquid lipids [27, 28]. Apart from type 
of liquid its concentration also has a significant effect on the PS of the NLCs which could be 
attributed to the swollen core of the nanoparticles loaded with liquid lipid.  As the amount of 
the oil increases reduced emulsifying efficiency leads to higher surface tension and larger 
particles are formed. This corroborates with  several previous reports [29, 30]. These 
observations are also elaborated in the contour plots (Figure 2. B) 
X2 had a negative effect on the PS with highest impact when DO was used as liquid lipid and 
least when PGMC was employed in the NLC formulation. Higher concentration of surfactant 
results in reduction in the surface tension and production of particles with small sizes whereas 




yielding larger size particle [31, 32]. Furthermore, the surface activity of the surfactant offer 
stabilisation  and prevent coalescence of nanoparticles [33].  X3 relatively had low impact on 
PS as evident from the small values of coefficient of X3 in equations 4 – 9. However, the 
interaction between (X1-X3) had a positive effect on PS with liquid lipid concentration having 
more powerful impact than amount of drug added to NLCs. This effect is also evident in the 
contour plots (Figure 2. A). 
 
3.2.3. Influence of investigated parameters on PDI 
PDI is measure of the heterogeneity of sizes of particles in a mixture and an indicator of 
aggregation in the particles. The PDI values of <0.250 suggest that the nanoparticles exist in 
monodispersed distribution, with low variability and aggregation [34]. NLCs prepared using 
different liquid lipids varied in PDI values between 0.11 to 0.45. As PS was impacted positively 
with increase in liquid lipid concentration we would expect an increase in PDI at higher 
concentrations of oil due to the increase in the agglomeration of the particles as a consequence 
of the Van der Waal attraction forces resulting in polydisperse formulations [23]. However, in 
exception to the two propylene glycol esters, PGMC and PGML which showed positive 
correlation, other liquid lipids either did not have much impact or resulted in formation of more 
homogeneous NLCs with increase in liquid lipid [35]. This is also evident from steep curvature 
of the RES-PGMC and RES-PGML in the perturbation plots signifying their higher influence 
on PDI (Figure 3.b). Of interest was the observation that at highest concentration of GTC, 
resulted in NLCs with low PDI (Figure 2.A & B) [8]. The influences of liquid lipids on PDI 
was in the following decreasing order: PGML>PGMC >PGC>GTC>DO>GTO>PCG. 
The effect of various parameters on the PDI is shown by the equations below: 
For GTC 
PDI= +0.35498-0.25950× X1-0.22717× X2+8.26667E-004× X3+0.18533× X1 × X2-1.53333E-
004×X1×X3-5.43333E-004×X2×X3+0.039000×X12+0.19033×X22-2.34167E-006X32          
Equation 10                      
For DO 
Y2= +0.26509-0.12600× X1-0.31917× X2+1.36917E-003× X3+0.18533× X1 × X2-1.53333E-








PDI= +0.061811-0.061500× X1+0.010333× X2+6.74167E-004× X3+0.18533× X1×X2-
1.53333E-004×X1×X3-5.43333E-004×X2×X3+0.039000×X12+0.19033×X22-2.34167E-
006X32                                                                                                          Equation 12                           
For PGMC 
PDI= +0.25382+1.16573E-015× X1-0.37767× X2+1.49167E-003× X3+0.18533× X1 × X2-
1.53333E-004×X1×X3-5.43333E-004×X2×X3+0.039000×X12+0.19033×X22-2.34167E-
006X32                                                                                                           Equation 13                               
For GTO      
PDI= +0.35697-0.12000× X1-0.42267× X2+1.29667E-003× X3+0.18533× X1 × X2-1.53333E-
004×X1×X3-5.43333E-004×X2×X3+0.039000×X12+0.19033×X22-2.34167E-006X32           
Equation 14                        
For PGML 
PDI=+0.27357+0.044000×X10.30917×X2+1.10417E003×X3+0.18533×X1×X21.53333E004×
X1×X3-5.43333E-004×X2×X3+0.039000×X12+0.19033×X22-2.34167E-006X32              
Equation 15 
Increasing the amount of Tween 80 concentration led to better homogeneity in PS and reduced 
aggregation (equations 10-15). Higher amount of surfactant is known to cover the nanoparticles 
surface better thus preventing their coalescence [36]. If the thickness of the surfactant layer is 
high relative to NLC diameter, an efficient steric protection is assured, and the coalescence is 
prevented. The addition of higher amount of drug led to increased heterogeneity of NLC as 
demonstrated by the positive coefficient of this factor for all six type of liquid lipids (Figure 
2. A & B). 
The interaction between the concentration of liquid lipid and the surfactant had a positive effect 
on the PDI, signifying their increase will cause increase in the PDI. Tween 80 concentration 




containing NLCs did not show much effect on PDI. Furthermore, amount of drug only showed 
prominent perturbation effect with NLCs prepared using PCG on the PDI.  
 
3.2.4. Influence of investigated parameters on ZP 
Generally, high ZP (negative or positive) is considered as a main contributing factor for the 
stability of the colloidal dispersions. Generally, ZP of ±30 mV is considered suitable to get a 
stable NLC dispersion because of electrical repulsion between the particles. ZP of NLCs varied 
in the range of -21.3 to -39.9 mV. The negative charge can be associated with the presence of 
hydroxyl ions on the surface of the lipid nanostructures [37]. Moreover, polyphenolic drug or 
free fatty acids and partial glycerides present in the oils or phospholipids used as stabilizers 
would also contribute to the negative electrical charge of the NLCs [38].The quadratic 
polynomial equations below summarize the effect of three independent variables on the ZP of 
six liquid lipids NLCs: 
For GTC 
ZP = -54.56346+11.23333 x X1+35.46667 xX2 +0.062667xX3+3.06667x X1xX2 -0.041333x 
X1 xX3-2.66667E-003x X2 x X3 +0.26667 x X12 -17.20000x X22 -1.33333E-004x X32      
Equation 16 
For DO   
ZP = -51.13269 +8.93333xX1+37.51667x X2 +0.045417x X3+3.06667x X1 x X2-0.041333x 
X1 x X3-2.66667E-003xX2xX3+0.26667xX12-17.20000xX22-1.33333E-004xX32                        
Equation 17                                                
For PCG  
ZP =-38.50673-0.016667x X1 +28.76667x X2 +0.046417x X3 +3.06667x X1 x X2 -0.041333x 
X1 xX3-2.66667E-003xX2xX3+0.26667xX12-17.20000xX22-1.33333E-004xX32                     
Equation 18                                               
For PGMC  
ZP = -47.67308 -7.26667x X1 +38.31667x X2 +0.050917x X3 +3.06667x X1 x X2 -0.041333x 
X1 xX3-2.66667E-003xX2xX3+0.26667xX12-17.20000xX22-1.33333E-004xX32                    




For GTO  
ZP = -53.78462 +2.13333x X1 +38.76667x X2 +0.075667x X3 +3.06667x X1 xX2 -
0.041333xX1 xX3-2.66667E-003xX2xX3+0.26667xX12-17.20000xX22-1.33333E-004xX32                   
Equation 20                                                                         
For PGML  
ZP = -42.83942 -1.31667x X1+26.66667x X2+0.057417x X3+3.06667x X1 x X2-0.041333x 
X1 x X3-2.66667E-003xX2xX3+0.26667xX12-17.20000xX22-1.33333E-004xX32                    
Equation 21                                                   
The hydrophilic liquid lipids played a more prominent role contributing to the increase in the 
negative surface charge (equations 16-21), due to the adsorption of free hydroxyl ions present 
in these liquid lipids. Increase in their concentration resulted in higher ZP and improved 
stability with their influence in order PGMC>PCG>PGML.  While increasing the 
concentration of lipophilic liquid lipids which do not possess any free hydroxyl groups resulted 
in lowered ZP and decreased NLC stability with their influence in order of GTC>DO>GTO.  
Tween 80 being a non-ionic surfactant with an HLB value of 15 being adsorbed on the surface 
of particles causes reduction in the net charge at the particle surface, resulting in negatively 
charged NLCs [39]. Surfactant concentration showed higher effect on zeta potential with 
PGMC, GTO, GTC and DO containing NLCs (Figure 3. c). Increasing the RES content 
resulted in increased negative charge on NLCs as would be expected due to polyphenolic 
structure of the drug. However, the overall influence of drug amount was less on ZP as 
concluded from the lower coefficient values of X3 and 2-D contour plots (Figure 2. A & B). 
The interaction between the factors (X1-X2 and X1- X3) for all liquid lipid type had positive 
effect on the ZP. Interestingly, the interaction between X2- X3 had a negative effect on the ZP 
even though both factors individually demonstrated a positive effect on the response.  
 
3.2.5. Influence of investigated parameters on EE 
EE of RES in all the NLC formulations with six liquid lipids were observed to be in range of 
91.9 to 99.5% with NLCs with DO showing the highest EE. The influence of liquid lipid on 
EE was in the order DO>PCG>GTC>PGMC>GTO>PGML. High EE >90% for all NLCs 
could be attributed to crystal imperfections that provide more space for drug incorporation [32]. 








3-1.38400×X12+3.78800×X22-2.81267E-004×X32                                           Equation 22                               
For DO  
EE=+97.14014-
5.71900×X19.28967×X2+0.069875×X3+0.29733×X1×X2+0.020640×X1×X3+0.018607×X2×X




















The amount of drug added in the NLCs showed most significant and a positive effect on the 
EE (equations 22-27). This is attributed to more drug being available for the entrapment in the 
internal phase which is also illustrated by the steep curvature for this factor in perturbation 
plots (Figure 3.d). Increasing the concentration of surfactant lead to lowered EE as higher 
amount of deposition of surfactant on the interface between the water and the lipid phase 
reduced interfacial tension which would increase the shear pressure generated during the 
homogenization process that would result in the formation of small emulsion droplet and thus 
decreasing the EE [40]. The interaction between (X1-X2, X1 X3 and X2 X3) for all liquid lipids 
had a positive effect on the EE even though X1and X2 showed a negative effect on the EE, but 
the combination with the third factor X3 made the interaction positive (Figure 2. A & B). This 
can be used to predict interactions and determine the optimised formulation with desirable 
value of the response variable. 
 
3.2.6. Influence of investigated parameters on DL 
Drug loading is the major challenge in the formulation of nanoparticles, especially for poorly 
water-soluble drugs. Because of the disturbance in of the solid lipid crystal order achieved by 
incorporation  of liquid lipid, higher drug incorporation due to more space to accommodate 
drug molecules can be obtained in NLCs  as compared to SLNs [41]. Compared with the 
reported solubility of RES in water (300 mg/100 mL) [42] the solubility of RES in lipid 
matrices consisting of trimyristin and different oils was improved by at least 33.3 folds. The 
DL of various formulated NLCs ranged between 2.93 to 7.55%, which indicates that the 
response was extremely sensitive toward the studied factors. The physicochemical properties 
of liquid lipid play a critical role on the DL in the NLC formulations. Labrasol, a PEGylated 
lipid with high HLB and solubility for the drug, resulted in higher DL as compared to GTO, 
DO and GTC which had lower solubility for the drug and lower HLB values. A substantially 
higher DL was achieved with RES-NLC-PCG as compared to a previous report on RES lipid 
nanoparticles [43] which was followed by the two polyethylene glycol esters PGML and 
PGMC showing comparable drug loading. 
Increasing the amount of liquid lipids resulted in RES-NLCs with higher DL [29], as 
demonstrated by positive coefficients of X1, the influence of liquid lipid concentration was in 
the following order PGMC>PCG>GTO>PGML>GTC>DO. This is attributed to the increase 
in the auxiliary spaces in the lipid matrix due to distortion of its crystalline structure by the 




surfactant concentration and the amount of drug also impact the RES loading in the NLCs, 
which is demonstrated by the following quadratic equations. 
 
For GTC 
DL= -3.36946+3.31783× X1+7.79100× X2+0.039990× X3-0.12600× X1 × X2-3.64000E-003× 
X1 × X3+5.67000E-003×X2×X3-2.53333×X12-6.11133×X22-4.13667E-005×X32              
Equation 28                                          
For DO 
DL= -5.18163 +2.23283× X1+10.78100× X2+0.039805× X3-0.12600× X1 × X2-3.64000E-
003× X1 × X3+5.67000E-003×X2×X3-2.53333×X12-6.11133×X22-4.13667E-005×X32                     
Equation 29                                                           
For PCG 
DL= -5.03404+4.31733× X1+9.04800× X2+0.042647× X3-0.12600× X1 × X2-3.64000E-003× 
X1 × X3+5.67000E-003×X2×X3-2.53333×X12-6.11133×X22-4.13667E-005×X32                      
Equation 30                                                
For PGMC 
DL= -4.81689+4.39033× X1+8.67450× X2+0.042885× X3-0.12600× X1 × X2-3.64000E-003× 
X1 × X3+5.67000E-003×X2×X3-2.53333×X12-6.11133×X22-4.13667E-005×X32                      
Equation 31                                                
For GTO 
DL= -5.74321+3.74583× X1+9.04100× X2+0.049065× X3-0.12600× X1 × X2-3.64000E-003× 
X1 × X3+5.67000E-003×X2×X3-2.53333×X12-6.11133×X22-4.13667E-005×X32               








DL= -4.78191+3.72333× X1+9.12850× X2+0.041120× X3-0.12600× X1 × X2-3.64000E-003× 
X1 × X3+5.67000E-003×X2×X3-2.53333×X12-6.11133×X22-4.13667E-005×X32               
Equation 33                      
It is evident that the Tween 80 concentration exerted a positive effect with enhanced entrapped 
drug as apparent from the positive values of the coefficient (X2) in equations 28-33. X3 had a 
positive effect on the DL with higher drug being entrapped inside the nanoparticles when more 
drug was added [32, 44]. This is also evident from the perturbation plots (Figure 3.e). 
Interestingly, the interaction between factors (X1-X2) and (X1- X3) for all the types of liquid 
lipids had a negative effect on the %DL, even though all three factors had a positive effect on 
this response when taken individually (Figure 2.A & B). On the other hand, the interaction 
between (X2- X3) demonstrated a positive effect, which signifies that any increase in each of 
these factors will lead to the increase in the DL.  
  
3.2.7. Design Space 
Design space is referred as the multidimensional combination and interaction of input variables 
and process parameters that have been demonstrated to provide assurance of quality [45] and  
was obtained by overlaying the critical response contours with overlay plot (Figure 4). The 
yellow coloured regions describe the design space with suitable response values and grey 
regions illustrate where response values did not meet the quality product attributes. Based on 
the overlay plot and desirability function (Figure S3) criteria the optimized formulations can 
be selected from the design space. The selection of the optimized NLCs was based upon 
accomplishing the minimum particle size (50 to 100 nm), lowest PDI value (0.11 to 0.30), 
formation of stable particles (ZP) (-37 to -21 mV) maximum value of EE (94 to 99.54%) and 
maximum DL (3.00 to 7.55%) (Table 4). This model can be used to navigate the design space. 
3.3. Differential Scanning Calorimetry (DSC)  
DSC is a well-established technique that offers a close look of the melting and crystallization 
behaviour of crystalline material like lipid nanoparticles to characterize the physical and 
chemical changes in either their enthalpy or the heat capacity of the lipid [46]. 
DSC thermogram of trimyristin displayed a sharp endothermic peak at 58.32⁰C (Figure 5.A). 
The addition of all six liquid lipids to trimyristin caused a depression  in its melting point (MP) 




liquid lipid, whereby the maximum reduction of MP occurred at the highest concentration of 
each of the oil. The reduction of onset temperature on addition of each of the liquid lipids to 
trimyristin followed the subsequent order PGMC < PGML< DO< GTC< GTO < PCG.  The 
difference between the melting and the peak onset temperatures is the point at which the 
melting of the lipid occurs after addition of the liquid lipid, and the greater difference infers 
higher disordered state of the crystals. The lower concentrations of liquid lipids resulted in a 
lower difference (around 2 degrees), whereas when concentration of the oils was increased to 
0.75%, major differences between the onset and the melting temperature was observed 
indicating greater disorder in the structure (Figure S4.a) [48].  The highest difference between 
melting and peak onset temperature was demonstrated by PGMC (6 degrees) clearly causing 
maximum distortion in the crystal lattice of trimyristin. This is in corroboration with a previous 
report  showing a linear correlation between the concentration of oil and the melting point 
depression indicating complete incorporation of liquid lipid [49]. The data also demonstrated 
reduction in the melting enthalpy of the solid lipid on addition of liquid lipids with maximum 
reduction being revealed by GTO (Figure S4.b). Trimyristin with an enthalpy of 134.62 J/g in 
the bulk, its value was reduced to 94.39, 95.37, 102.43, 106.34, 107.78 and 110.93 J/g on 
addition of GTO, DO, PCG, PGMC, PGML and GTC, respectively. For the less ordered crystal 
state, the melting of the solid lipid required less energy to overcome the lattice force. 
 
DSC analysis was also performed to study the effect of the incorporation of different liquid 
lipids on the crystallinity of RES and its melting behaviour (Figure 5.B). Addition of liquid 
lipids to RES showed a concentration dependent depression in its MP with a linear correlation. 
RES demonstrated a sharp endothermic peak at 267.49⁰C which was distinctly shifted to 4.21, 
105.41, 218.76, 237.52, 247.19 and 258.29⁰C in presence of PGMC, PCG, PGML, DO, GTC 
and GTO, respectively. We can observe that nature of liquid lipid had huge impact on 
depression of MP of RES, with PGMC causing great disturbance and distortion of the crystal 
lattice of RES. At the highest concentration (0.75%) of PGMC, the drug was completely 
dissolved and the thermogram did not therefore reveal any endothermic peak of drug indicating 
it to be in amorphous form, though at lower concentrations of PGMC the crystallinity of drug 
was still maintained. In comparison to other liquid lipids, PCG showed the lowest onset 
temperature and lowest melting temperature (Figure S5.a). It also elicited greatest difference 
between the melting and the onset temperatures indicating greatest distortion of the drug crystal 
lattice by PCG. This was followed by PGML>DO>GTC>GTO respectively, which also 




possess higher saturation solubility than crystalline materials; however, amorphous drugs in 
metastable state can spontaneously recrystallize and lead to a decreasing bioavailability during 
the process of storage. To avoid this, the ideally produced nanoparticle system should be 
crystalline [50, 51]. In this context, DO and GTO showed well-defined peak of RES at all oil 
concentrations indicating maintenance of crystalline structure of the drug even at high 
concentrations of liquid lipid [51] Data also depicted a significant decrease in the melting 
enthalpy of RES with a maximum reduction observed when the concentration of liquid lipids 
was at highest level (Figure S5.b) resulting in a less ordered crystalline state where the melting 
of the drug required less energy to overcome lattice force [52]. Further the use of high melting 
point triglyceride, trimyristin may reduce the mobility of the drug molecules within the lipid 
core and thus reduce the drug expulsion upon storage [53, 54]. 
 
All drug loaded and blank NLCs showed a single endothermic peak in the range of 103–116⁰C 
(Figure 5. C). The crystallization of lipid in its bulk state occurs differently from its emulsified 
state. Usually a shift of melting transition to a lower temperature is expected in a NLCs than 
the bulk lipid attributed to its small size. However, trimyristin NLCs showed endothermic peak 
at higher temperatures as compared to bulk lipid (58.32⁰C). This could be due to faster 
polymorphic transitions of lipid crystals in NLCs due to their small size than in bulk [54]. 
Further emulsifiers present in NLCs are known to promote b crystallization which is more 
stable and higher melting polymorph [55]. Further the chemical nature of liquid lipid 
influenced the melting behavior of the solid lipid in the NLCs. Addition of the two hydrophobic 
long chain oleates DO and GTO exhibited a shift to higher melting points, 116 and 111⁰C 
respectively, than other more hydrophilic liquid lipids (103-104⁰C). The shift in endothermic 
peak along with the absence of characteristic RES endothermic peak at 267.14⁰C suggested 
interaction of RES with lipid components and indicated that RES entrapped in lipids was in 
amorphous state or dispersed molecularly in the NLCs [56].    
    
3.4. Storage stability of RES-NLCs 
PS and PDI of nanoparticles are two important criteria as these factors play a critical role in 
cellular uptake, drug release rate, bioavailability and bio-distribution to various tissues and  the 
stability of the formulated products [57]. NLCs have the advantage of improved DL and 
controlled drug release and have demonstrated good stability in terms of PS and prevention of 




to examine if the nature of liquid lipid determines the stability of the NLCs.  The six optimised 
NLCs containing six different liquid lipids (Table 4) were selected in order to study their 
stability and effect of long-term storage at two different temperatures 4°C and 20°C on the PS, 
PDI, ZP, EE and DL. 
 
The stability studies clearly demonstrated that the type of liquid lipid greatly influenced the 
CQAs of the NLCs.  The mean PS at 4°C of all NLCs was below 100 nm (Figure 6. a) except 
the one containing PGML which showed increased PS of 209.8 ±11.6nm at the end of one 
month (Figure 7.A.b). The NLCs containing the PEGylated liquid lipids, Labrasol and the two 
propylene glycol esters, PGML and PGMC showed increase in PS to <200 nm at the end of 3 
months with some aggregation as demonstrated by peaks in the micron region in particle size 
distribution curves (Figure 7A.c) [59]. The particles grew in size with time with higher degree 
of aggregation at the end of six months with mean PS of above 200 nm for PCG, PGMC and 
PGML containing NLCs, while the NLCs formulated with two triglycerides GTO and GTC 
and the fatty acid ester DO maintained the mean PS below 200 nm even at the end of six months 
(Figure 7A.d). This could be explained due to probable migration of these liquid lipids towards 
the interface as compared to the more nonpolar oils which remained mixed with solid lipid 
trimyristin due their structural similarity. Previous studies have shown medium chain 
triglycerides to have stabilising effect on the long chain triglyceride emulsion when prepared 
as mixed emulsion [60]. Furthermore, crystallisation of drug at low temperature can contribute 
to increase in PS. The NLCs stored at 20⁰C showed better stability with mean PS well 
maintained below 100 nm up to three months (Figure 6.a). However, beyond three months, 
NLCs containing PGMC and PGML showed a significant increase in the PS which increased 
above 100 nm at the end of six months (Figure 7A.f & g).  
The PDI values for all formulations stored at 4°C showed an increase after one month except 
for GTC containing NLCs, which maintained low PDI (0.27 ± 0.03) (Figure 6.b). After three 
months of storage, NLCs with PCG and PGMC were highly polydisperse with distinct 
aggregation. Six months stability data showed an overall increase of PDI above 0.3 for all the 
NLCs. Meanwhile, NLCs stored at 20°C revealed no pronounced changes in the PDI. This 
could probably be due to better maintenance of lipid structure and drug remaining entrapped 
within it at ambient temperature, whereas storage at lower temperature lead to crystallization 
of the drug and eventually increase in the PS of NLCs [61, 62]. The increase in PS on storage 




ripening. Flocculation and coalescence lead usually to a wide particle size distribution with a 
high PDI [37]. 
Coalescence phenomenon is described by the equation 34: 
 
1/r2 =/r20 -8π/3ωt                                                 Equation 34 
Where r is the average of radius of NLCs, r0 is the radius value at t= 0 and ω is the frequency 
of rupture per unit of surface of the film [62]. Another mechanism for instability is Ostwald 
ripening phenomenon, which describes the solubility of smaller particles due to high surface 
energy within the dispersion medium and redeposit onto larger particles [61].  The Ostwald 
ripening rate can be evaluated by applying the principal, which predicts a linear relationship 
between the cube of particle radius, r3, and time t, ω being the slope of plots (equation 35) [62]. 
 
ω = dr3/ dt = 8/ 9 [C ∞γ (MD / ρ2RT)]                   Equation 35 
The main physicochemical mechanism contributing to particle growth of the NLCs is due 
Ostwald ripening more than coalescence and flocculation (Figure 8.a & b). The plots of 
change of PS (radius, r3) with time for NLCs with PGMC, DO, PGML and PCG exhibited 
Oswald ripening as phenomenon for particle growth as evident from r2 values (Table S1) This 
could be associated to higher solubility of these oils in aqueous phase.However, NLCs with 
GTO and GTC showed coalescence to be the main mechanism of particle growth as evident 
from linear plots of 1/r2vs. t (Table S1). When PGMC was used as liquid lipid in NLCs, PS 
grew exponentially with time with large particles visible at the end of six months and the 
mechanism for particle grow might be attributed to flocculation (Figure 8.a & b). 
  
ZP reflects the electric charge on the particle surface and is a key indicator for predicting the 
long-term physical stability of colloidal dispersion system [63]. It was interesting to note that 
though ZP of the fresh NLCs prepared with six different liquid lipids were not significantly 
different from each other (Figure 7 B. a), time dependent change in ZP was strongly influenced 
by the type of liquid lipid carrier (Figure 6.c). After storage at 4°C, the ZP of the NLCs 
prepared with the triglycerides, GTO and GTC showed no evident reduction in the ZP value in 
the first month (Figure 7 B. b). This validates the PS and PDI results substantiating that the 
triglycerides with low melting point can impart stability to the NLC dispersions. Also DO 
containing NLCs did not show a reduction of ZP value in the first month while propylene glycol 
esters PGML and PGMC containing NLCs revealed sharp decline in ZP (-11.1 mV) 




ZP value (Figure 7 B. c) for all NLCs were observed which further deteriorated at the end of 
six-months on storage at 4°C (Figure 7B. d). The generation of long  b-crystals of trimyristin 
during storage with their re-orientation and differently charged crystal side on the surface could 
be responsible for the variation in the ZP [64]. NLCs with GTO, PCG and GTC at 20°C showed 
good stability for the first three months (Figure 7B.e &f). In addition, NLCs with the 
triglycerides, GTO and GTC showed minimal change of ZP at the end of six months, while all 
other formulations had a significant reduction in their ZP values over the period of six months 
(Figure 7B.g). Thus, the stability of NLCs in terms of PS and ZP was much better when stored 
at 20°C rather than 4°C. 
  
With NLCs stored at 4°C, the entrapped drug remained stable with no change in the total drug 
content after one month (Figure 6.d). However, only NLCs containing GTO showed good 
stability upon storage at 25°C for the first month (Figure 6.d). After 3 months, all formulations 
showed a significant decrease in drug content regardless of their storage conditions, potentially 
suggesting degradation of the drug with time. RES being prone to thermal degradation and at 
pH above 6.8, could be the cause for  lowered drug content in the formulation on long term 
storage [65]. 
The EE depends on the concentration and the type of lipid mixture utilized in formulating the 
NLCs. Incorporation of RES resulted in a high EE, because of the lipophilic nature of the drug. 
While all NLCs stored at both 4°C and 20°C showed significant difference in EE from the 
initial observed values (Figure 6.e) however still the values were reasonably high above 90% 
EE. The high EE despite of low drug content is probably due to minimum drug leakage from 
the nanoparticles in spite of the degradation of the drug. Overall, NLCs made from GTO as a 
liquid lipid showed the best stability as compared to other NLCs over the mentioned period of 
time, maintaining average particle size less than 100 nm, monodisperse formulation and 
requisite EE and DL when stored at 20°C. This is in confirmation with DSC results which 
showed that crystalline structure of the drug was maintained in presence of GTO thus avoiding 
any amorphous metastable state or spontaneous recrystallization which contribute to instability 
of NLCs. 
Conclusion 
Past decade has seen dramatic escalation in the NLC based formulations reported in the 
literature, however there is no trend or direction in the selection of solid or liquid lipids and 




clearly demonstrated the impact the different liquid lipids with varied chemical compositions, 
molecular structures and HLB have on the critical quality parameters, thermal behaviour and 
stability of NLCs. The more lipophilic oils, the two triglycerides GTO, GTC and the long chain 
fatty acid ester DO yield NLCs with lower PS as compared to the hydrophilic oils (PGC, PGMC 
and PGML). Though increasing the concentration of liquid lipid increased the PS of NLCs, 
however the impact on its polydispersity varied with the type of lipids with propylene glycol 
esters, PGMC and PGML showing positive correlation. The DL was dependent on the 
solubilizing effect of liquid lipid and its influence on the crystallinity of the drug and solid 
lipid. The varied liquid lipids not only impacted the degree of MP depression of solid lipid but 
also the crystallinity of drug and finally the stability of NLCs. The particle growth whether 
Oswald’s ripening or coalescence or flocculation was also affected by the attributes of the 
liquid lipid incorporated in the NLCs. Finally, tuneable NLCs with RES as model drug could 
be manufactured with particles size (˂100 nm), particle size distribution (˂ 0.3), with 
negatively charged surface (-24 mV), high EE (91-99 %) and DL (2-7%) within the established 
design space, which may serve as useful carrier for the oral delivery of the bioactive. Further 
the study informs the rational design and provides vital insight on selection of liquid lipids and 
its significance for future development of NLCs for various drug delivery applications. 
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Figure 1. Solubility studies of RES in various lipid lipids (n = 3), error bars represent the 















































             
           
   
  
   
      
                                                                                                           
 
  
Figure 2. A) 2-D contour plots showing the effect of liquid lipid concentration and 
amount of drug at medium level of Tween 80 concentration on various response 
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Figure 2. B) 2-D contour plots showing the effect of liquid lipid and Tween 80 
concentration at low level of drug on various response variables of NLCs: (a) PS, (b) 
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Figure 3) Perturbation plots showing the interactions between the liquid lipid 
concentration Tween 80 concentration  and drug amount, all at medium level on variouse 
response variables of NLCs with different type of liquid lipids (a) PS, (b) PDI, (c) (ZP), 
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Figure 4) Overlay plots showing the location of optimized formulation with respect to the 
relationship between different responses to liquid lipid concentration and the drug 
amount for six different liquid lipid based NLCs (a) NLC with GTC, (b) NLC with DO, 
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Figure 5A) DSC Thermograms showing the effect of oil concentration on the solid lipid a. GTC b. DO c. PCG d. PGMC e. GTO f. PGML 
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Figure 5.B) DSC Thermograms showing the effect of oil concentration on resveratrol solubility a. GTC, b. DO, c. PCG, d. PGMC, e. 
GTO, f. PGML 
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Figure 5.C) DSC heating thermogram of different RES-NLCs, B-NLCs, solid lipid, resveratrol and physical mixtures of a. GTC b. DO c. 
PCG d. PGMC e. GTO f. PGML 
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Figure 6. Storage stability of NLC at 4°C and 20°C at Initial (day zero), three months and six months and effect on (a) Particle size, (b) 
Polydispersity index,( (c) Zeta potential, (d)  Total drug and (e)  Entrapment efficiency, error bars are standard error of the mean, 












b c d 




Figure 7 A) Overlay size distribution measured by zeta-sizer for stability of RES-NLCs after a. Initial (day zero) b. One, c. Three and d. Six 




Figure 7 B) Overlay zeta potential measured by zeta-sizer for stability after (a) Initial (day zero) (b). One, (c). Three and D. Six months for 

































































































Figure 8) Stability study of NLCs (a) Coalescence force and (b) Ostwald ripening versus time determined for NLCs stored at 4⁰C, (c) 
























Table 1: Physicochemical properties of liquid lipids and Resveratrol 
 
Liquid lipid  
  Chemical formula 
 




HLB Value Chemical name Brand name 
PEG-8 caprylic/capric 
glycerides (PCG) 
Labrasol NA PEGylated lipid <20 14 
Propylene glycol 
monocaprylate (type II) 
NF (PGMC) 
Capryol 90 C11H22O3 Propylene glycol ester <20 6 
Propylene Glycol 
Monolaurate (PGML) 
Lauroglycol 90 C15H30O3 PEGylated lipid <20 5 
Glyceryl trioleate 
(GTO) 
Triolein C57H104O6 C18:1 triglyceride 5 0 
Decyl octadec-9-enoate 
(DO) 
Decyl oleate C28H54O2 Fatty acid ester <20 NA 
Glycerol tricaprylate 
(GTC) 
Miglyol 808 C27H50O6 C8:0 triglycerides 9-10 7 
Drug Solubility 
(mg/100mL) 
Log P Melting point (ºC) pKa Molecular mass (g/mol) Molecular formula  




Table 2: Experimental factors and levels in the Box-Behnken design for Resveratrol NLCs 
 
 
Factor Levels Used, Actual (Coded) 
 
Low (-1)            Medium (0)                      High 
(+1) 
 
A (X1) = Concentration of Liquid lipid (%)                                      0.25                      0.5                    
0.75 
B (X2) = Tween 80 concentration (%)                                              0.5                        0.75                     
1 
C (X3) = Amount of drug (mg)                                                          100                       150                    
200 
D= Liquid lipid type                                                                             GTO, GTC, PGMC, 
PGML, PCG, DO 
 
Dépendent Variables                                                               Contraints 
PS = Particle Size                                                                      ˂ 100 nm 
PDI= Polydispersity Index                                                        ˂ 0.3 
ZP = Zeta Potential                                                           ± 30 mV 
EE = Entrapment Efficiency                                                     Maximum 



























 Table 3: Analysis of variance (ANOVA) - Lack-of-fit test for each of the response variables 
  




F-value p value 
(Prob >F) 
Particle size  Model DEL 18622.31 29 642.15 4.91 0.0001* 
Residual  6283.71 48 130.91   
Cumulative 
Total  
24906.02 77    
Polydispersity Index       
Model  0.18 29 6.216E-003 2.58 0.0018* 
Residual  0.12 48 2.410E-003   
Cumulative 
Total  
0.3 77    
 Zeta potential      
Model  2835.60 29 97.78 0.85 0.6797 
Residual  5545.04 48 115.52   
Cumulative 
Total  
8380.64 77    
 Entrapment  
      Efficiency  
     
Model  168.41 29 5.81 4.79 <0.0001* 
Residual  58.22 48 1.21   
Cumulative 
Total  
226.63 77    
Drug Loading       
Model  138.14 29 4.76 21.80 0.0001* 
Residual  10.49 48 0.22   
Cumulative 
Total  
148.63 77    
 



















Table 4: Compositions of the optimized Resveratrol NLCs formulations for the long-term 
stability studies 
Formulation Liquid lipid concentration 
(%) 
of the total mixture of lipids  
Tween 80 concentration 
(%) 
RES-NLC-GTO 0.5 1 
RES-NLC-PCG 0.25 0.75 
RES-NLC-PGMC 0.25 0.75 
RES-NLC-PGML 0.5 1 
RES-NLC-DO 0.5 1 












































            
            




Figure S1: Linear correlation plots between the actual and the predicted values of various 
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Figure S2:  Linear correlation plots between the actual and the predicted values of different 
types of liquid lipids on different response variables of NLCs a. PS, b. PDI, c. ZP, d. EE and 
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Figure S3: Desirability of the design space for different liquid lipid types at medium Tween 
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Figure S4. Bar graph representing a. Decrease of melting point, onset temperature and 
increase in the width of melting area of solid lipid with different concentrations of liquid 
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Solid lipid /liquid lipid ratio (%)
Onset temperature (⁰C) 0.75% Oil Onset temperature (⁰C) 0.5 % Oil 
Onset temperature (⁰C) 0.25 % Oil Melting point (⁰C) 0.75 % Oil
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Figure S5. Bar graph representing a. Decrease of melting point, onset temperature and 
increase in the width of melting area of RES with different concentrations of liquid lipids 
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Resvertrol/liquid lipid ratio (%)
Onset temperature (⁰C) 0.75 % Oil Onset temperature (⁰C) 0.5 % Oil
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Table S1: R2 values for determining coalescence and Ostwald ripening mechanism for 
particle growth for six different RES-NLCs at both 4⁰C and 20⁰C 
 
4⁰C storage temperature 20⁰C storage temperature 
Formulations  Coalescence  
R2 value for  
1/r2 vs t plot 
Ostwald 
ripening 
 R2 value for  
r3vs t plot 
Coalescence  
R2 value for  
1/r2 vs t plot 
Ostwald ripening 
R2 value for  
r3vs t plot 
RES-NLC-
GTO 
0.909 0.839 0.877 0.818 
RES-NLC-
PCG 
0.662 0.951 0.486 0.519 
RES-NLC-
PGMC 
0.495 0.827 0.860 0.788 
RES-NLC-
PGML 
0.722 0.912 0.970 0.864 
RES-NLC-
DO 
0.792 0.815 0.526 0.509 
RES-NLC-
GTC 
0.925 0.878 0.772 0.774 
 
 
 
